Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential FMC-220 is a first-in-class covalent activator of p53Y220C designed to address potency and tolerability challenges of non-covalent approachesIn preclinical...

Congrats to ⁦‪Frontier Medicines‬⁩ on their covalent p53 Y220C activator FMC-220! www.globenewswire.com/news-release...

Exciting science at the Advances in Therapeutic Symposium in Frankfurt! #goTPD #molecularGlues

www.theranova.eu/en/veranstal...

So privileged that CHI-Healthtech brought their flagship #DDC conference to Europe, in sunny ☀️ Barcelona! Enjoying tapas and sangria with Heide Düvel @chemb.bsky.social @rpnowak.bsky.social Gopal Sapkota, Ed Tate @nurkocaturk.bsky.social Hannah Peters, Rima Alawar. Thanks for the invitation Tanuja!

Through a series of cryo-EM structures, this study shows how an E2 and ubiquitin itself can play a "structural" role to specify ubiquitin linkage. 🧪
Lovely work by Katrina Warner, @moritzhunkeler.bsky.social @kheewoongbaek.bsky.social, @katherinedonovan.bsky.social and others in the Fischer Lab!

Online! An engineered cereblon optimized for high throughput screening and molecular glue discovery by H. Bailey, J. Eisert, Fiona Sorrell @Fi_in_Frankfurt, Ivan Dikic @iDikic2 et al at @goetheuni @IBC2_GU @MPIBP @merckgroup http://dlvr.it/TGRD4Y

Hi BlueSky! Now expanding reach here as well. Go go #ScienceTwitter or should it be #ScienceBlueSky?

Was great to contribute to this story together with
JanGerhartz Dominika Pienkowska Ina Dressel & Thomas Geiger from the lab. #CRBN #Interactome #GLUES
authors.elsevier.com/sd/article/S...
Animation credit PROXIDRUGs. Thanks for fantastic colaboration.